News | March 04, 2021
COVAXIN demonstrates interim clinical efficacy of 81%
Bharat Biotech expects to share further details of the trial results as additional data become available.
Bharat Biotech expects to share further details of the trial results as additional data become available.
The company plans to submit the vaccine for regulatory review
The initiative will be led by David Baker, 2024 Nobel Prize winner in Chemistry, IPD director, professor of biochemistry, and HHMI Investigator at the University of Washington
The company, part of pharma powerhouse AbbVie, will showcase the findings—and the next evolution of its AA Signature framework—at AMWC 2026 in Monaco,
Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer
The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
A disinfectant credited with helping contain some of the world’s most dangerous livestock diseases is marking a major milestone
Subscribe To Our Newsletter & Stay Updated
